MedTrace Logo

Impact of Delta Opioid Receptor Gene (OPRD1) Variations on Treatment Outcome in African Americans

NCT02225184 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 81

Last updated 2019-01-03

No results posted yet for this study

Summary

Background:

\- Differences in peoples genes can make them respond to drugs in different ways. Methadone and buprenorphine are two drugs used to treat drug addiction. A study showed that African Americans with a certain genetic marker did better using one kind of drug treatment over the other. Researchers want to see if they can repeat these findings. They also want to study other things that affect how well people do in treatment.

Objective:

\- To see if certain genetic markers and other facts about a person s life can predict how well they do in treatment for addiction to opioids and cocaine.

Eligibility:

\- African American adults age 18 and over. They must be former or current participants in an Archway Treatment Clinic study. They must have been on a stable dose of either study drug for at least 12 weeks. They also must have given urine samples regularly for at least 10 weeks.

Design:

* Participants will come to the clinic for 1 visit lasting about 2 hours.
* Participants will give 1 teaspoon of blood for genetic testing. They will be asked if their sample can be used in future studies.
* If researchers cannot get enough blood, they will do a cheek swab. This will collect skin cells for genetic testing.
* Participants will fill out 3 questionnaires.
* Results of genetic testing and answers to questionnaires will be kept private.

Conditions

  • Genetic Underpinning of Substance Abuse
  • Polymorphism-genetic
  • Drug Abuse/Dependence
  • Opiod-Related Disorders

Sponsors & Collaborators

  • National Institute on Drug Abuse (NIDA)

    lead NIH

Principal Investigators

  • Karran A Phillips, M.D. · National Institute on Drug Abuse (NIDA)

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2014-08-23
Primary Completion
2018-12-31
Completion
2018-12-31

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02225184 on ClinicalTrials.gov